## KPJ HEALTHCARE BERHAD

(Incorporated in Malaysia)

## UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2002

	<u>Note</u>		9 months ended	
		<u>30.9.2002</u> RM	<u>30.9.2001</u> RM	
CASH FLOWS FROM/(USED IN) OPERA	TING ACTIVITIES			
Net profit attributable to shareholders		9,396,483	9,326,434	
Adjustments for:				
Taxation Minority interest Property, plant and equipment - depreciation		3,855,858 122,816 5,197,687	3,209,580 163,211 4,620,000	
<ul> <li>loss (gain) on disposal</li> <li>Amortisation of nurse training costs</li> <li>Interest income</li> <li>Interest expense</li> </ul>		(14,830) 1,146,179 (1,717,152) 220,014	4,344 980,177 (1,362,542) 248,162	
Allowance for doubtful debts		902,120	846,542	
Operating profit before changes in working capital		19,109,176	18,035,908	
Changes in working capital:				
Inventories Receivables Payables Intercompany balances		(754,386) (2,454,367) 558,993 (7,617,110)	(501,870) (3,227,016) 1,260,298 (3,671,690)	
Cash generated from/(used in) operations		8,842,305	11,895,630	
Interest paid Income tax paid		(220,014) (4,447,879)	(248,162) (3,348,386)	
Net cash from/(used in) operating activities	3	4,174,412	8,299,082	
CASH FLOWS FROM/(USED IN) INVEST	ING ACTIVITIES			
Purchase of property, plant and equipment Proceeds from sale of property,	İ	(10,304,522)	(10,757,963)	
plant and equipment Additions in nurse training costs Acquisition of additional interest in		14,830 (2,074,024)	(2,201,380)	
subsidiary company	A11	(428,254)	(105,000)	
Deposits pledged with banks Interest received		1,717,152 	(195,000) 1,362,542	
Net cash (used in)/from investing activities		(11,074,818)	(11,791,801)	

## KPJ HEALTHCARE BERHAD

(Incorporated in Malaysia)

## UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENTS FOR THE NINE MONTHS ENDED 31 DECEMBER 2001 (CONTINUED)

CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES         8,103,510         7,830,574           Drawdown of borrowing Dividends paid Dividends paid Dividends paid to minority shareholders of subsidiary companies (14,000) (1,728,000 Long term deposits received 22,500 247,000         (14,000) (11,296 22,500 247,000 24
CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES  Drawdown of borrowing 8,103,510 7,830,574 Dividends paid (4,128,000) (1,728,000 Dividends paid to minority shareholders of subsidiary companies (14,000) (11,296 Long term deposits received 22,500 247,000  Net cash from/(used in) financing activities 3,984,010 6,338,278
Drawdown of borrowing  Dividends paid  Dividends paid (4,128,000)  Dividends paid to minority shareholders of subsidiary companies  Long term deposits received  Net cash from/(used in) financing activities  Response (14,000)  22,500  247,000  06,338,278
Dividends paid Dividends paid to minority shareholders of subsidiary companies Long term deposits received  Net cash from/(used in) financing activities  (4,128,000) (1,728,000) (11,296) (22,500) (247,000) (15,296) (14,000) (11,296) (14,000) (14,
Dividends paid to minority shareholders of subsidiary companies (14,000) (11,296 Long term deposits received 22,500 247,000 Net cash from/(used in) financing activities 3,984,010 6,338,278
companies Long term deposits received  Net cash from/(used in) financing activities  NET CHANGES IN CASH AND  (14,000) 22,500 247,000 247,000 6,338,278
Long term deposits received 22,500 247,000  Net cash from/(used in) financing activities 3,984,010 6,338,278  NET CHANGES IN CASH AND
NET CHANGES IN CASH AND
(2,010,000)
CACH AND CACH FOLINAL ENTO AT DECININING
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL YEAR 6,122,039 1,396,305
CASH AND CASH EQUIVALENTS AT END
OF THE FINANCIAL YEAR 3,205,643 4,241,864
DEPOSITS, CASH AND BANK BALANCES
Deposits with licensed banks 3,898,652 1,619,304
Deposits with financed companies 100,000 100,000
Cash and bank balances       350,102       3,017,560         Bank overdraft       (648,111)       -
Bank overdraft (648,111) -
3,700,643 4,736,864
less: Deposits pledged with licensed banks (495,000) (495,000
CASH AND CASH EQUIVALENTS 3,205,643 4,241,864